H.H. Helgason 1 , J.Y. Engwegen 2 M. Zapatka 3 , M. Kuiper 1 , A. Cats 1 , H. Boot 1
Serum proteomic profiling in patients with advanced gastric cancer receiving first – line epirubicine, cisplatin and capecitabine chemotherapy and identification.
